BioLife Solutions, Inc. (BLFS)

In May 2026, BioLife Solutions reported strong first-quarter financial results, showing revenue growth and a return to GAAP profitability, but the stock declined after an initial surge. In April 2026, the company won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal CryoCase, which positively impacted the stock. In February 2026, the company reported its fourth-quarter and full-year 2025 financial results, showing revenue growth and optimistic 2026 revenue guidance. Late 2025/Early 2026, the company divested non-core assets to focus on high-margin biopreservation media and cell processing tools. The stock has experienced some volatility, with a decline of about 3.3% over the past year, and insider selling has been noted.

The provided search results do not contain explicit information regarding the demand seasonality for BioLife Solutions' products and services. However, the company's focus on supporting ongoing clinical trials and commercial manufacturing of cell and gene therapies suggests a demand driven by the continuous nature of research, development, and production in the biopharma industry, rather than strong seasonal fluctuations.

BioLife Solutions, Inc. is a life sciences company focused on developing, manufacturing, and marketing bioproduction products and services for the cell and gene therapy and broader biopharma markets. Its core business includes cell processing tools and services, biopreservation media, and related solutions. Major products include biopreservation media like CryoStor and HypoThermosol, cell processing tools such as human platelet lysates and CellSeal vials, ThawSTAR automated thawing devices, and Evo shipping containers (though the evo business was divested in October 2025).

BioLife Solutions, Inc. operates and markets its products and services in the United States, Europe, the Middle East, Africa, and internationally, with the majority of its revenue generated from the United States.

BioLife Solutions has maintained a strong brand reputation, receiving the INTERPHEX 2026 Biotech Innovation Award for its CellSeal CryoCase. The company is recognized as a leading supplier of cell processing tools and services for the CGT market, with its biopreservation media considered foundational tools. BioLife Solutions has secured regulatory validation through clinical trials and FDA Master Files, establishing a durable market position. The company's strategic focus on high-margin biopreservation consumables has further enhanced its reputation.

Institutional investors are the dominant owners of BioLife Solutions, Inc., holding a significant majority of the company's shares. Key institutional stakeholders include Casdin Capital, LLC, BlackRock, Inc., Invesco Ltd., Vanguard Group Inc., Fred Alger Management, Llc and State Street Corp. Insider ownership stood at 1.85% as of July 2025 and 2.20% as of May 2026.